Biosimilar drug market competition results in significantly reduced costs
Eight years after biosimilar drugs were introduced to the prescription drug market, researchers from the USC Schaeffer Center have studied the cancer drug trastuzumab (Herceptin) and five similar medications as an example of biosimilars’ potential … Read More »